Paycor HCM (NASDAQ:PYCR – Get Free Report) had its price target upped by equities researchers at The Goldman Sachs Group from $19.00 to $21.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. The Goldman Sachs Group’s price objective would suggest a potential upside of 15.83% from the company’s current price.
A number of other analysts have also recently commented on PYCR. JPMorgan Chase & Co. cut their target price on shares of Paycor HCM from $19.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, August 15th. UBS Group decreased their target price on Paycor HCM from $18.00 to $15.00 and set a “neutral” rating on the stock in a research report on Friday, August 16th. Jefferies Financial Group increased their price objective on Paycor HCM from $13.00 to $15.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. Truist Financial dropped their target price on shares of Paycor HCM from $33.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, August 13th. Finally, BTIG Research decreased their price target on shares of Paycor HCM from $26.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, August 15th. Nine equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $19.31.
View Our Latest Stock Report on PYCR
Paycor HCM Stock Performance
Insider Activity
In related news, Director Jeremy Rishel sold 3,723 shares of Paycor HCM stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $14.02, for a total value of $52,196.46. Following the completion of the sale, the director now owns 21,218 shares in the company, valued at approximately $297,476.36. This trade represents a 14.93 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.39% of the company’s stock.
Institutional Investors Weigh In On Paycor HCM
Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Paycor HCM by 11.5% in the first quarter. Vanguard Group Inc. now owns 6,884,980 shares of the company’s stock valued at $133,844,000 after purchasing an additional 710,370 shares during the period. Bank of New York Mellon Corp grew its stake in Paycor HCM by 149.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 607,996 shares of the company’s stock worth $7,722,000 after purchasing an additional 364,025 shares in the last quarter. Marshall Wace LLP increased its holdings in Paycor HCM by 1,234.9% during the 2nd quarter. Marshall Wace LLP now owns 370,985 shares of the company’s stock worth $4,712,000 after purchasing an additional 343,194 shares during the period. ING Groep NV acquired a new stake in Paycor HCM in the 3rd quarter valued at about $4,615,000. Finally, Cubist Systematic Strategies LLC boosted its stake in shares of Paycor HCM by 207.5% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 465,097 shares of the company’s stock valued at $5,907,000 after buying an additional 313,851 shares during the period. 36.76% of the stock is owned by institutional investors and hedge funds.
About Paycor HCM
Paycor HCM, Inc, together with its subsidiaries, provides software-as-a-service (SaaS) human capital management (HCM) solutions for small and medium-sized businesses (SMBs) primarily in the United States. It offers cloud-native platform to address the comprehensive people management needs of SMB leaders.
See Also
- Five stocks we like better than Paycor HCM
- What is a Secondary Public Offering? What Investors Need to Know
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Stock Splits, Do They Really Impact Investors?
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- How to Use Stock Screeners to Find Stocks
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Paycor HCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paycor HCM and related companies with MarketBeat.com's FREE daily email newsletter.